Broncus Holding Corp
HKEX:2216
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.46
0.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Broncus Holding Corp
Accounts Receivables
Broncus Holding Corp
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Broncus Holding Corp
HKEX:2216
|
Accounts Receivables
$10m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Accounts Receivables
¥41.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Accounts Receivables
¥1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
6%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Accounts Receivables
¥4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Accounts Receivables
¥72m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Accounts Receivables
¥3.3B
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Broncus Holding Corp
Glance View
Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
See Also
What is Broncus Holding Corp's Accounts Receivables?
Accounts Receivables
10m
USD
Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Accounts Receivables amounts to 10m USD.
What is Broncus Holding Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
50%
Over the last year, the Accounts Receivables growth was 16%. The average annual Accounts Receivables growth rates for Broncus Holding Corp have been 50% over the past three years .
You don't have any saved screeners yet
